12:00 AM
Aug 11, 2008
 |  BioCentury  |  Regulation



According to Vanda (NASDAQ:VNDA), trials of iloperidone that included Risperdal risperidone produced skewed results because patients and physicians assumed that patients who didn’t experience Risperdal’s well-known side effects had not been randomized to active treatment. This led to higher discontinuation rates in the iloperidone arms than among patients who received Risperdal, according to the company. In one Phase III study conducted by Novartis (NYSE:NVS; SWX:NOVN), Study 3 below, iloperidone discontinuation rates were about 1.5 times those for Risperdal and similar to placebo. The discontinuation rate for Risperdal was slightly lower than iloperidone in Study 2. Discontinuation rates were similar for all...

Read the full 519 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >